Follicular Lymphoma Pipeline Analysis Report 2025
Description
Follicular lymphoma is a slow-growing, indolent form of non-Hodgkin lymphoma that primarily affects the lymphatic system. It accounts for 20%-30% of all non-Hodgkin lymphoma (NHL) cases globally. Despite various treatment options, there remains a significant unmet clinical need for more effective therapies, as current options, such as chemotherapy and immunotherapy, may lead to relapse or resistance. The follicular lymphoma pipeline analysis by Expert Market Research focuses on various treatment options for this disease. Emerging follicular lymphoma drugs, including CAR T-cell therapies and bispecific antibodies, show promise in improving patient outcomes and addressing this ongoing medical challenge.
Report Coverage
The Follicular Lymphoma Pipeline Analysis Report by Expert Market Research gives comprehensive insights into follicular lymphoma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for follicular lymphoma. The follicular lymphoma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The follicular lymphoma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with follicular lymphoma treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to follicular lymphoma.
Follicular Lymphoma Pipeline Outlook
Follicular lymphoma (FL) is a slow-growing, non-Hodgkin lymphoma originating from B-lymphocytes. It occurs when genetic mutations, often involving the BCL2 gene, cause uncontrolled cell division and inhibit apoptosis. This leads to enlarged lymph nodes, fatigue, and weight loss. FL typically develops in lymphoid tissues but can spread to other organs, making early detection essential for effective management.
Follicular lymphoma treatments include chemotherapy, immunotherapy, and targeted therapies to inhibit cancer cell growth. Radiation therapy is effective for localized disease, while stem cell transplantation is an option for aggressive or relapsed cases. Newer treatments, such as CAR-T cell therapy, show promise in enhancing patient outcomes and extending remission periods. In June 2024, the United States Food and Drug Administration granted accelerated approval to Epcoritamab-bysp (Epkinly®) for treating relapsed or refractory follicular lymphoma, following positive results from the EPCORE® NHL-1 trial.
Follicular Lymphoma Epidemiology
Follicular lymphoma is the most common low-grade non-Hodgkin lymphoma, representing 20%-30% of all non-Hodgkin lymphoma cases. In the United States, follicular lymphoma has an incidence of 6 cases per 100,000 people annually. The United Kingdom reports around 2,300 new cases each year, while in India, follicular lymphoma constitutes approximately 7.2% of non-Hodgkin lymphoma cases.
Follicular Lymphoma Pipeline Therapeutic Assessment
This section of the report covers the analysis of follicular lymphoma drug candidates based on several segmentations, includ
By Phase
The pipeline report covers 50+ drug analyses based on phase:
The follicular lymphoma pipeline analysis report covers 50+ drug analyses based on drug classes:
The pipeline assessment report 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total follicular lymphoma clinical trials, with47.37%, highlighting strong mid-stage development activity. Phase I follows at 41.18%, indicating robust early-stage innovation. Phase III accounts for 10.84%, showing promising advancements nearing regulatory review. Early phase I contributes 0.62%, reflecting exploratory efforts. This balanced pipeline can significantly boost treatment options for follicular lymphoma.
Follicular Lymphoma – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the follicular lymphoma pipeline analysis include monoclonal antibodies, small molecules, bispecific antibodies, CAR T-cell therapies, antibody-drug conjugates, and others. The follicular lymphoma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for follicular lymphoma. Chimeric antigen receptor (CAR) T-cell therapies are emerging as promising options in the follicular lymphoma treatment pipeline. For instance, lisocabtagene maraleucel (Breyanzi) received FDA accelerated approval in May 2024 for adults with relapsed or refractory follicular lymphoma after two or more systemic therapies. It showed a 95.7% overall response rate in the Phase 2 TRANSCEND-FL trial.
Follicular Lymphoma Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR report for the follicular lymphoma pipeline report covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed follicular lymphoma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in follicular lymphoma clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for follicular lymphoma. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of follicular lymphoma drug candidates.
Drug: Tazemetostat
Tazemetostat (TAZVERIK), an EZH2 inhibitor developed by Epizyme, Inc., is being evaluated in a Phase 3 trial for relapsed/refractory follicular lymphoma (FL). This study examines its efficacy, safety, and pharmacokinetics when combined with Lenalidomide and Rituximab, aiming to improve progression-free survival in patients with EZH2 mutations or limited treatment options. Tazemetostat is a first-in-class EZH2 methyltransferase , targets EZH2 mutations in follicular lymphoma. It inhibits tumor growth by reversing gene silencing, offering potential therapeutic benefits.
Drug: SHR2554
SHR2554 is a selective oral EZH2 inhibitor that disrupts cancer cell growth by targeting H3K27Me3 levels, inducing apoptosis, and inhibiting lymphoma progression, offering promising therapeutic potential. Jiangsu Hengrui Medicine Co., Ltd. is sponsoring a Phase II, single-arm, open-label study to evaluate the efficacy and safety of SHR2554 in patients with relapsed or refractory follicular lymphoma. SHR2554 is an oral inhibitor of EZH2 , a targeted therapy for lymphomas.
Drug: AZD0486
AZD0486, sponsored by AstraZeneca, is currently being evaluated in a global Phase III study for previously untreated follicular lymphoma. This bispecific T-cell engager , developed using UniRat technology, targets immune checkpoints. The objective is to assess its efficacy and safety in combination with rituximab, compared to standard immunochemotherapy regimens. AZD0486 is administered intravenously.
Key Questions Answered in the Follicular Lymphoma – Pipeline Insight Report
The Follicular Lymphoma Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for follicular lymphoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into follicular lymphoma collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Global Non-Hodgkin’s Lymphoma Treatment Market
Global Clinical Trials Market
Report Coverage
The Follicular Lymphoma Pipeline Analysis Report by Expert Market Research gives comprehensive insights into follicular lymphoma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for follicular lymphoma. The follicular lymphoma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The follicular lymphoma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with follicular lymphoma treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to follicular lymphoma.
Follicular Lymphoma Pipeline Outlook
Follicular lymphoma (FL) is a slow-growing, non-Hodgkin lymphoma originating from B-lymphocytes. It occurs when genetic mutations, often involving the BCL2 gene, cause uncontrolled cell division and inhibit apoptosis. This leads to enlarged lymph nodes, fatigue, and weight loss. FL typically develops in lymphoid tissues but can spread to other organs, making early detection essential for effective management.
Follicular lymphoma treatments include chemotherapy, immunotherapy, and targeted therapies to inhibit cancer cell growth. Radiation therapy is effective for localized disease, while stem cell transplantation is an option for aggressive or relapsed cases. Newer treatments, such as CAR-T cell therapy, show promise in enhancing patient outcomes and extending remission periods. In June 2024, the United States Food and Drug Administration granted accelerated approval to Epcoritamab-bysp (Epkinly®) for treating relapsed or refractory follicular lymphoma, following positive results from the EPCORE® NHL-1 trial.
Follicular Lymphoma Epidemiology
Follicular lymphoma is the most common low-grade non-Hodgkin lymphoma, representing 20%-30% of all non-Hodgkin lymphoma cases. In the United States, follicular lymphoma has an incidence of 6 cases per 100,000 people annually. The United Kingdom reports around 2,300 new cases each year, while in India, follicular lymphoma constitutes approximately 7.2% of non-Hodgkin lymphoma cases.
Follicular Lymphoma Pipeline Therapeutic Assessment
This section of the report covers the analysis of follicular lymphoma drug candidates based on several segmentations, includ
By Phase
The pipeline report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
The follicular lymphoma pipeline analysis report covers 50+ drug analyses based on drug classes:
- Monoclonal Antibodies
- Small Molecules
- Bispecific Antibodies
- CAR T-Cell Therapies
- Antibody-Drug Conjugates
- Others
The pipeline assessment report 50+ drug analyses based on the route of administration.
- Oral
- Parenteral
- Others
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total follicular lymphoma clinical trials, with47.37%, highlighting strong mid-stage development activity. Phase I follows at 41.18%, indicating robust early-stage innovation. Phase III accounts for 10.84%, showing promising advancements nearing regulatory review. Early phase I contributes 0.62%, reflecting exploratory efforts. This balanced pipeline can significantly boost treatment options for follicular lymphoma.
Follicular Lymphoma – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the follicular lymphoma pipeline analysis include monoclonal antibodies, small molecules, bispecific antibodies, CAR T-cell therapies, antibody-drug conjugates, and others. The follicular lymphoma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for follicular lymphoma. Chimeric antigen receptor (CAR) T-cell therapies are emerging as promising options in the follicular lymphoma treatment pipeline. For instance, lisocabtagene maraleucel (Breyanzi) received FDA accelerated approval in May 2024 for adults with relapsed or refractory follicular lymphoma after two or more systemic therapies. It showed a 95.7% overall response rate in the Phase 2 TRANSCEND-FL trial.
Follicular Lymphoma Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR report for the follicular lymphoma pipeline report covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed follicular lymphoma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in follicular lymphoma clinical trials:
- Novartis Pharmaceuticals
- Celgene Corporation
- Epizyme, Inc.
- Jiangsu HengRui Medicine Co., Ltd.
- Xynomic Pharmaceuticals, Inc.
- Epizyme, Inc.
- Pharmacyclics LLC.
- Hoffmann-La Roche
- XEME Biopharma Inc.
- AstraZeneca
- Regeneron Pharmaceuticals
- Genmab A/S
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for follicular lymphoma. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of follicular lymphoma drug candidates.
Drug: Tazemetostat
Tazemetostat (TAZVERIK), an EZH2 inhibitor developed by Epizyme, Inc., is being evaluated in a Phase 3 trial for relapsed/refractory follicular lymphoma (FL). This study examines its efficacy, safety, and pharmacokinetics when combined with Lenalidomide and Rituximab, aiming to improve progression-free survival in patients with EZH2 mutations or limited treatment options. Tazemetostat is a first-in-class EZH2 methyltransferase , targets EZH2 mutations in follicular lymphoma. It inhibits tumor growth by reversing gene silencing, offering potential therapeutic benefits.
Drug: SHR2554
SHR2554 is a selective oral EZH2 inhibitor that disrupts cancer cell growth by targeting H3K27Me3 levels, inducing apoptosis, and inhibiting lymphoma progression, offering promising therapeutic potential. Jiangsu Hengrui Medicine Co., Ltd. is sponsoring a Phase II, single-arm, open-label study to evaluate the efficacy and safety of SHR2554 in patients with relapsed or refractory follicular lymphoma. SHR2554 is an oral inhibitor of EZH2 , a targeted therapy for lymphomas.
Drug: AZD0486
AZD0486, sponsored by AstraZeneca, is currently being evaluated in a global Phase III study for previously untreated follicular lymphoma. This bispecific T-cell engager , developed using UniRat technology, targets immune checkpoints. The objective is to assess its efficacy and safety in combination with rituximab, compared to standard immunochemotherapy regimens. AZD0486 is administered intravenously.
Key Questions Answered in the Follicular Lymphoma – Pipeline Insight Report
- Which companies/institutions are leading the follicular lymphoma drug development?
- What is the efficacy and safety profile of follicular lymphoma pipeline drugs?
- Which company is leading the follicular lymphoma pipeline development activities?
- What is the current follicular lymphoma commercial assessment?
- What are the opportunities and challenges present in the follicular lymphoma pipeline landscape?
- What is the efficacy and safety profile of follicular lymphoma pipeline drugs?
- Which company is conducting major trials for follicular lymphoma drugs?
- Which companies/institutions are involved in follicular lymphoma collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in follicular lymphoma?
The Follicular Lymphoma Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for follicular lymphoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into follicular lymphoma collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Global Non-Hodgkin’s Lymphoma Treatment Market
Global Clinical Trials Market
Table of Contents
200 Pages
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology & Assumptions
- 2 Executive Summary
- 3 Overview of Follicular Lymphoma
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Diagnosis
- 3.5 Treatment
- 4 Patient Profile: Follicular Lymphoma
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Follicular Lymphoma: Epidemiology Snapshot
- 5.1 Follicular Lymphoma Incidence by Key Markets
- 5.2 Follicular Lymphoma – Patients Seeking Treatment in Key Markets
- 6 Follicular Lymphoma: Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 Follicular Lymphoma: Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 Follicular Lymphoma, Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of Follicular Lymphoma Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 Follicular Lymphoma Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
- 10.1 Comparative Analysis for Late-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 Drug: Tazemetostat
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 Drug: Ibrutinib
- 10.2.3 Other Drugs
- 11 Follicular Lymphoma Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 Drug: SHR2554
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 Drug: Abexinostat
- 11.2.3 Other Drugs
- 12 Follicular Lymphoma Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
- 12.1 Comparative Analysis for Early-Stage Drugs
- 12.1.1 Study Type
- 12.1.2 Recruitment Status
- 12.1.3 Company
- 12.1.4 Funder Type
- 12.2 Product Level Analysis*
- 12.2.1 Drug: VAY736
- 12.2.1.1 Product Description
- 12.2.1.2 Trial ID
- 12.2.1.3 Sponsor Name
- 12.2.1.4 Study Type
- 12.2.1.5 Drug Class
- 12.2.1.6 Eligibility Criteria
- 12.2.1.7 Study Record Dates
- 12.2.1.7.1 First Submitted
- 12.2.1.7.2 First Posted
- 12.2.1.7.3 Last Update Posted
- 12.2.1.7.4 Last Verified
- 12.2.1.8 Indication
- 12.2.1.9 Study Design
- 12.2.1.10 Recruitment Status
- 12.2.1.11 Enrollment (Estimated)
- 12.2.1.12 Location Countries
- 12.2.2 Other Drugs
- 13 Follicular Lymphoma Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
- 13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
- 13.1.1 Study Type
- 13.1.2 Recruitment Status
- 13.1.3 Company
- 13.1.4 Funder Type
- 13.2 Product Level Analysis*
- 13.2.1 Drug 1
- 13.2.1.1 Product Description
- 13.2.1.2 Trial ID
- 13.2.1.3 Sponsor Name
- 13.2.1.4 Study Type
- 13.2.1.5 Drug Class
- 13.2.1.6 Eligibility Criteria
- 13.2.1.7 Study Record Dates
- 13.2.1.7.1 First Submitted
- 13.2.1.7.2 First Posted
- 13.2.1.7.3 Last Update Posted
- 13.2.1.7.4 Last Verified
- 13.2.1.8 Indication
- 13.2.1.9 Study Design
- 13.2.1.10 Recruitment Status
- 13.2.1.11 Enrollment (Estimated)
- 13.2.1.12 Location Countries
- 13.2.2 Other Drugs
- 14 Follicular Lymphoma, Key Drug Pipeline Companies
- 14.1 Novartis Pharmaceuticals
- 14.1.1 Company Snapshot
- 14.1.2 Pipeline Product Portfolio
- 14.1.3 Financial Analysis
- 14.1.4 Recent News and Developments
- 14.2 Celgene Corporation
- 14.2.1 Company Snapshot
- 14.2.2 Pipeline Product Portfolio
- 14.2.3 Financial Analysis
- 14.2.4 Recent News and Developments
- 14.3 Epizyme, Inc.
- 14.3.1 Company Snapshot
- 14.3.2 Pipeline Product Portfolio
- 14.3.3 Financial Analysis
- 14.3.4 Recent News and Developments
- 14.4 Jiangsu HengRui Medicine Co., Ltd.
- 14.4.1 Company Snapshot
- 14.4.2 Pipeline Product Portfolio
- 14.4.3 Financial Analysis
- 14.4.4 Recent News and Developments
- 14.5 Xynomic Pharmaceuticals, Inc.
- 14.5.1 Company Snapshot
- 14.5.2 Pipeline Product Portfolio
- 14.5.3 Financial Analysis
- 14.5.4 Recent News and Developments
- 14.6 Pharmacyclics LLC.
- 14.6.1 Company Snapshot
- 14.6.2 Pipeline Product Portfolio
- 14.6.3 Financial Analysis
- 14.6.4 Recent News and Developments
- 14.7 Hoffmann-La Roche
- 14.7.1 Company Snapshot
- 14.7.2 Pipeline Product Portfolio
- 14.7.3 Financial Analysis
- 14.7.4 Recent News and Developments
- 14.8 XEME Biopharma Inc.
- 14.8.1 Company Snapshot
- 14.8.2 Pipeline Product Portfolio
- 14.8.3 Financial Analysis
- 14.8.4 Recent News and Developments
- 14.9 AstraZeneca
- 14.9.1 Company Snapshot
- 14.9.2 Pipeline Product Portfolio
- 14.9.3 Financial Analysis
- 14.9.4 Recent News and Developments
- 14.10 Regeneron Pharmaceuticals
- 14.10.1 Company Snapshot
- 14.10.2 Pipeline Product Portfolio
- 14.10.3 Financial Analysis
- 14.10.4 Recent News and Developments
- 14.11 Genmab A/S
- 14.11.1 Company Snapshot
- 14.11.2 Pipeline Product Portfolio
- 14.11.3 Financial Analysis
- 14.11.4 Recent News and Developments
- 15 Regulatory Framework for Drug Approval, By Region
- 16 Terminated or Suspended Pipeline Products
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
